• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country

    6/25/24 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials
    Get the next $EVGN alert in real time by email

    Current castor seed production is expected to support the supply of the new order in 2024, valued at ~ $440K 

    REHOVOT, Israel, June 25, 2024 /PRNewswire/ -- Casterra Ag Ltd., a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), is a provider of an integrated solution for industrial-scale cultivation of castor plants based on its elite castor seed varieties, developed for bio-based industries including, biofuels & biopolymers. Casterra is pleased to announce the receipt of an additional purchase order valued at ~$440K from an existing customer. This order expands Casterra's operations into a new African country and solidifies Casterra's unique offering in the bio-fuel market.

    Evogene

    Mr. Yoash Zohar, CEO of Casterra states: "This additional order reflects the confidence in Casterra's capabilities and in our castor seed varieties, developed utilizing Evogene's GeneRator AI tech-engine and Casterra's advanced breeding methods, and marks a significant step in our expansion into Africa. We expect that our previously announced seed production, now totaling 900 tons, will more than support this order, which is expected to be completed by Q4 2024, as well as earlier purchase orders received last year. Casterra remains committed to being a world leader in castor seed development and production and promoting sustainable biofuel production globally." 

    Casterra anticipates that the remaining revenue from castor seed orders received during 2023 and in 2024, which were not supplied to date (including the order described in today's PR), will be approximately ~$8.4 million, reflecting a price adjustment due to late delivery of the order from 2023. Based on the planned production this year, Casterra expects to recognize revenues in this amount in the second half of 2024.

    The global biodiesel market size was estimated at $36.48 billion in 2022 and it is expected to hit around $79.12 billion by 2032, expanding at a notable CAGR of 8.1% from 2023 to 2032[1]. Biofuels offer significant advantages over conventional petrochemical fuels, presenting a renewable and biodegradable alternative with substantially lower negative environmental impact. Castor oil emerges as a standout non-fossil oil candidate due to its carbon-neutral and other properties making it compliant with tightening European regulatory standards.

    Casterra's high oil-yielding varieties have been developed with traits which make the castor plants grown suitable for large scale farming on marginal soils in semi-arid conditions. Castor plants and the castor oil produced have the potential of becoming a major sustainable feedstock for the global bio-fuel industry – without competing with food crops over prime land. 

    [1] https://www.precedenceresearch.com/biodiesel-market

    About Casterra AG Ltd.: 

    Casterra, a wholly owned subsidiary of Evogene, is an integrated solutions company for growing castor plants, based on its elite castor seed varieties, for bio-based industrial applications, such as biofuels & biopolymers. It has built its castor genetic assets based on a broad collection of over 300 castor lines from 40 different geographic and climatic regions. As part of its development process, Casterra applies advanced breeding methods utilizing Evogene's GeneRator AI tech-engine, enabling cutting-edge plant genomics tools and agro-technique expertise to enable efficient and sustainable industrial-scale production of the castor bean. 

    For more information, please visit http://www.casterra.co 

    About Evogene Ltd.: 

    Evogene (NASDAQ:EVGN, TASE: EVGN))) is a computational biology company aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines – MicroBoost AI, ChemPass AI, and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). 

    Evogene uses its tech-engines to develop products through subsidiaries and strategic partnerships. Evogene's subsidiaries currently utilize the tech-engines to develop novel life science products including human microbiome-based therapeutics by Biomica, ag-biologicals by Lavie Bio, ag-chemicals by AgPlenus, and castor seed varieties, for the biofuel and other industries, by Casterra. 

    For more information, please visit www.evogene.com 

    Forward Looking Statements

    This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statement in this press release when it discusses Casterra's ability to supply this purchase order and that its previously announced seed production will support this order as well as earlier purchase orders received last year. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between Israel, Hamas and Hezbollah and any worsening of the situation in Israel such as further mobilizations or escalation in the northern border of Israel,  and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions. 

    Evogene IR Contact:

    Rachel Pomerantz Gerber 

    Head of Investor Relations at Evogene 

    [email protected]

    Tel: +972-8-9311901  

    Logo: https://mma.prnewswire.com/media/1947468/Evogene.jpg

    Logo: https://mma.prnewswire.com/media/1947467/Casterra.jpg   

    Casterra Logo

     

    Cision View original content:https://www.prnewswire.com/news-releases/casterra-announces-an-additional-purchase-order-to-supply-castor-seeds-to-a-new-african-country-302181383.html

    SOURCE Casterra Ag Ltd.

    Get the next $EVGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVGN

    DatePrice TargetRatingAnalyst
    11/24/2021$8.00 → $7.00Outperform
    RBC Capital
    10/8/2021$7.00Buy
    ROTH Capital
    8/23/2021$8.00Outperform
    RBC Capital
    7/29/2021$10.00Buy
    Aegis Capital
    More analyst ratings

    $EVGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Evogene Ltd

    3 - Evogene Ltd. (0001574565) (Issuer)

    3/18/26 8:27:44 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 3 filed by Evogene Ltd

    3 - Evogene Ltd. (0001574565) (Issuer)

    3/18/26 8:24:25 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 3 filed by Evogene Ltd

    3 - Evogene Ltd. (0001574565) (Issuer)

    3/18/26 8:20:08 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    SEC Filings

    View All

    SEC Form 6-K filed by Evogene Ltd

    6-K - Evogene Ltd. (0001574565) (Filer)

    3/5/26 7:00:07 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form 6-K filed by Evogene Ltd

    6-K - Evogene Ltd. (0001574565) (Filer)

    2/25/26 8:00:32 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form D filed by Evogene Ltd

    D - Evogene Ltd. (0001574565) (Filer)

    2/19/26 4:01:05 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Leadership Updates

    Live Leadership Updates

    View All

    Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

    The collaboration is supported by a pan-European EUREKA grant, with participation of the Weizmann Institute of Science REHOVOT, Israel and MUNICH, Germany, Feb. 11, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a biotechnology company leveraging proprietary DNA barcoding technology for hyper-multiplexed pathway profiling in patient-derived iPSC models to accelerate drug discovery for complex disorders, and LMU University Hospital Munich, today announced a collaboration aiming to accelerate the devel

    2/11/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board

    Appointments Strengthen Scientific Leadership and Support the Acceleration of ChemPass AI™ for Drug and Ag-Chemical Discovery REHOVOT, Israel, Feb. 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational chemistry company focused on the AI-driven discovery and design of novel small molecules for the pharmaceutical and agricultural industries, today announced the appointment of Prof. John J. Irwin of the University of California, San Francisco (UCSF), and Prof. Dan T. Major of Bar-Ilan University (BIU) to its scientific advisory board (SAB). The

    2/9/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

    REHOVOT, Israel, Dec. 30, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, is pleased to announce the appointment of Dr. Olga Nissan as its Vice President of Business Development, effective as of January 1, 2026. Dr. Nissan is a seasoned biotechnology and pharmaceutical executive with extensive experience in bridging science, business, and funding. She has a proven track record of leading R&D, clinical develop

    12/30/25 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

    Conference will be held at Lisbon, Portugal - March 23–25, 2026 REHOVOT, Israel, March 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced it will be featured as a presenting company at the upcoming BIO-Europe Spring 2026 conference, being held on March 23-25, in Lisbon. Attending the conference on behalf of Evogene will be Dr. Gabi Tarcic, Chief Development Officer and Dr. Olga Nissan, VP Business Development. At the conference, Evogene will present the latest achievements of its pharma division. Dr. Niss

    3/9/26 9:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

    Conference call and webcast: today, March 05, 2026, 9:00 AM ETREHOVOT, Israel, March 5, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the fourth quarter and full year ended December 31, 2025.    Mr. Ofer Haviv, President & CEO of Evogene, stated: "During 2025, we executed a clear and decisive strategic shift. After a comprehensive review of our technology assets, target markets, and capital allocation priorities, we sharpened our focus to drive sustainable long-term value by co

    3/5/26 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Releases CEO Letter to Shareholders

    Updating on Strategic Progress and OutlookREHOVOT, Israel, Feb. 25, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries today issued a Letter to Shareholders from Ofer Haviv, President and Chief Executive Officer. Dear Evogene Shareholders,I am writing to update you on the significant progress Evogene has made over the past year and to outline the strategic transformation we initiated in 2025 to position the company for long-term value creation.During 2025, following a comprehensive review of our technology, markets, and capital

    2/25/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital reiterated coverage on EverGen Infrastructure with a new price target

    RBC Capital reiterated coverage of EverGen Infrastructure with a rating of Outperform and set a new price target of $7.00 from $8.00 previously

    11/24/21 7:31:39 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    ROTH Capital initiated coverage on Evogene with a new price target

    ROTH Capital initiated coverage of Evogene with a rating of Buy and set a new price target of $7.00

    10/8/21 8:30:09 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    RBC Capital initiated coverage on EverGen Infrastructure Corp. with a new price target

    RBC Capital initiated coverage of EverGen Infrastructure Corp. with a rating of Outperform and set a new price target of $8.00

    8/23/21 11:09:14 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Financials

    Live finance-specific insights

    View All

    Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

    Conference call and webcast: today, March 05, 2026, 9:00 AM ETREHOVOT, Israel, March 5, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the fourth quarter and full year ended December 31, 2025.    Mr. Ofer Haviv, President & CEO of Evogene, stated: "During 2025, we executed a clear and decisive strategic shift. After a comprehensive review of our technology assets, target markets, and capital allocation priorities, we sharpened our focus to drive sustainable long-term value by co

    3/5/26 7:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

    Zoom conference call scheduled for March 5, 2026, 9:00 AM ET REHOVOT, Israel, Feb. 19, 2026 /PRNewswire/ -- Evogene Ltd . (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the fourth quarter and full year 2025, on Thursday, March 5, 2026. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).To attend the conference, please register in advance: https://www.veidan-conferencing.com/evogene The entire conference will be

    2/19/26 8:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    Evogene Schedules Third Quarter 2025 Financial Results Release

    Zoom conference call scheduled for November 20, 2025, 9:00 AM ET REHOVOT, Israel, Nov. 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the third quarter of 2025, on Thursday, November 20, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To attend the conf

    11/6/25 9:00:00 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    $EVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Evogene Ltd

    SC 13G/A - Evogene Ltd. (0001574565) (Subject)

    10/15/24 6:52:26 AM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G filed by Evogene Ltd

    SC 13G - Evogene Ltd. (0001574565) (Subject)

    2/14/24 8:30:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials

    SEC Form SC 13G/A filed by Evogene Ltd (Amendment)

    SC 13G/A - Evogene Ltd. (0001574565) (Subject)

    2/11/22 12:15:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials